Pink SheetAdvanced therapy medicinal products (ATMPs) typically come with high price tags compared to more traditional medicinal treatments. While health technology assessment (HTA) agencies are willing to exer
ScripAmid the risk of a debt default due to a shortage of capital, bluebird bio has decided to quit the public markets and go private, with private equity firms Carlyle and SK Capital Partners acquiring it
ScripIn comparison to the broad S&P 500 index closing the year to 31 December 2024 up by over 24%, the fall by more than 3% in the NASDAQ Biotech Index (NBI) over the same period was a disaster. Specia
Pink SheetThe manufacturers of two high-cost gene therapies for sickle cell disease recently agreed to participate in CMS’s Cell and Gene Therapy Access Model, which could allow the companies to more widely mar